Halozyme Therapeutics seals two new agreements, sees shares soar
Global pharmaceutical company Bristol-Myers Squibb has recently partnered with Halozyme Therapeutics in order to obtain the license agreement to develop immuno-oncology medicines using the company’s Enhanze drug-delivery technology for an initial $105 million.
Halozyme’s Enhanze technology has been seen to reduce the time required to administer medications intravenously, and will provide long-term benefits within the delivery of patient-centered care in the way in which medication will be provided.
Bristol-Myers Squibb has designated multiple immuno-oncology targets, where the collaboration may extend to a maximum of 11 targets.
“We are excited to partner with Halozyme to pursue potential new approaches to how our medicines are delivered to patients,” said Murdo Gordon, Chief Commercial Officer, Bristol-Myers Squibb. “Through our work with Halozyme, we hope to improve the patient treatment experience by developing flexible and convenient treatment delivery options.”
- New technology could revolutionise traditional vaccines
- Terveystalo is set to enter the Helsinki Stock Exchange
- AstraZeneca and Aspen Group have inked a new partnership
Dr. Helen Torley, President and Chief Executive Officer of Halozyme said: “Through this collaboration we are excited to explore the potential for Enhanze to expand the number of cancer patients who may receive their therapies as a rapidly administered subcutaneous injection.”
Through this collaboration, Halozyme will gain the opportunity to receive milestone payments up to $160 million, plus royalties on sales of products using the Enhanze technology.
Halozyme has also recently licensed its Enhanze technology to Roche, where it will receive an initial $30 million, with potential to receive additional payments of up to $160 million in sales-based milestones and royalties.
"With each new licensing agreement, we see the potential for our global partners to advance their innovative therapies, reducing the treatment burden for patients, caregivers and payers through shorter administration times or a less frequent dosing regimen," commented Dr Torley.
With the prospect of increased revenue by up to $260 million, shares for Halozyme have increased
Slovenia launches EU COVID pass built on Better Platform
Slovenia has launched its EU Digital COVID Certificate, also known as the Digital Green Certificate, which was developed in only three weeks and built on top of a national clinical data repository (CDR) powered by the Better Platform.
The service generates a certificate based on the data available in Slovenia’s national CDR. The COVID certificate uses integrated care record data such as demographic data, vaccination and test result data that is already available. The data is made available through previously established services by the national COVID-19 screening data management solution and the national eVaccination registry – so there is no need for additional data to be generated solely for certificate purposes.
This rapid development of EU Digital Covid Certificate was made possible by an open-platform approach. It has also been created so that it can used by different systems, providing a vendor-neutral exchange of documents, and is available on-demand in digital or PDF form, with QR codes.
The COVID-19 pandemic pushed national health systems to quickly develop new digital solutions for including to manage epidemiological data, and organise COVID-19 tests and vaccinations. The EU Digital COVID Certificate is the latest example of a solution that was developed at this new fast pace to allow citizens to travel safely this summer.
The Slovenian healthcare system already had a national eHealth infrastructure, enabling data to be shared via an integrated care record that makes data available for any digital service instantly, at scale and volume.
Currently, Slovenia's healthcare system includes:
* more than 150 million health records for 2.1 million unique individuals (98% of the population)
* more than 86% (135 million) of records in the form of structured data that uses openEHR models
* more than 4 million records of COVID-19 test results
* unstructured data that includes discharge summaries, clinical notes, opt-in statements, consent documents and other clinical data
* data which is sent to the national system by more than 1,250 registered healthcare providers in Slovenia
Initially, the digital health platform enabled the Slovenian Ministry of Health to respond rapidly and deploy a COVID-19 screening data management solution on a county-wide level in just 14 days. With vaccination data available through the national eVaccination registry, there was no need for additional data to be generated solely to create the COVID certificate.
“We are happy that we already had the suitable IT infrastructure in place in Slovenia" said Minister of Health Janez Poklukar. "It allowed us to respond quickly and provide the necessary digital solutions that support the efforts of medical and epidemiological teams to manage the pandemic, as well as to allow our citizens to travel freely.”